Compare SILC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | IMUX |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | Israel | United States |
| Employees | N/A | 66 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 209.2M |
| IPO Year | 2002 | 2013 |
| Metric | SILC | IMUX |
|---|---|---|
| Price | $42.90 | $14.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 164.5K | ★ 167.0K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $0.51 |
| 52 Week High | $52.95 | $15.84 |
| Indicator | SILC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 59.86 |
| Support Level | $38.07 | $0.74 |
| Resistance Level | $51.05 | $15.81 |
| Average True Range (ATR) | 4.48 | 0.82 |
| MACD | -0.18 | -0.17 |
| Stochastic Oscillator | 31.99 | 53.80 |
Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.